Giovanna Sophia Manzano, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Encephalomyelitis, Acute Disseminated | 1 | 2021 | 66 | 0.840 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2021 | 53 | 0.820 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2018 | 37 | 0.700 |
Why?
|
| Multiple Sclerosis | 3 | 2022 | 2934 | 0.680 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2021 | 262 | 0.650 |
Why?
|
| Interferon Type I | 1 | 2020 | 498 | 0.640 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2021 | 654 | 0.630 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2022 | 506 | 0.620 |
Why?
|
| Muscular Diseases | 1 | 2020 | 555 | 0.600 |
Why?
|
| Methotrexate | 1 | 2021 | 1708 | 0.520 |
Why?
|
| Neuromyelitis Optica | 2 | 2022 | 205 | 0.340 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2021 | 3281 | 0.290 |
Why?
|
| HTLV-I Infections | 2 | 2015 | 102 | 0.270 |
Why?
|
| Human T-lymphotropic virus 1 | 2 | 2015 | 137 | 0.270 |
Why?
|
| Roseolovirus Infections | 1 | 2014 | 44 | 0.250 |
Why?
|
| Herpesvirus 6, Human | 1 | 2014 | 93 | 0.250 |
Why?
|
| Optic Neuritis | 2 | 2022 | 173 | 0.240 |
Why?
|
| Leukoencephalitis, Acute Hemorrhagic | 1 | 2021 | 16 | 0.220 |
Why?
|
| Dysarthria | 1 | 2021 | 54 | 0.210 |
Why?
|
| Plasmapheresis | 1 | 2021 | 210 | 0.210 |
Why?
|
| Seizures, Febrile | 1 | 2021 | 103 | 0.200 |
Why?
|
| Diplopia | 1 | 2021 | 177 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 2 | 2014 | 6293 | 0.190 |
Why?
|
| Confusion | 1 | 2021 | 261 | 0.180 |
Why?
|
| Methylprednisolone | 1 | 2020 | 401 | 0.180 |
Why?
|
| Virus Activation | 1 | 2021 | 326 | 0.180 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 282 | 0.180 |
Why?
|
| Alanine | 1 | 2020 | 592 | 0.170 |
Why?
|
| Clozapine | 1 | 2021 | 489 | 0.170 |
Why?
|
| Muscle Weakness | 1 | 2021 | 403 | 0.170 |
Why?
|
| Optic Nerve Diseases | 1 | 2020 | 320 | 0.160 |
Why?
|
| Tears | 1 | 2018 | 257 | 0.160 |
Why?
|
| Hematuria | 1 | 2018 | 235 | 0.160 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2021 | 667 | 0.150 |
Why?
|
| Prednisone | 1 | 2020 | 1556 | 0.140 |
Why?
|
| Herpesvirus 1, Human | 1 | 2021 | 727 | 0.140 |
Why?
|
| Craniopharyngioma | 1 | 2018 | 278 | 0.140 |
Why?
|
| Sarcoidosis | 1 | 2020 | 520 | 0.140 |
Why?
|
| Exanthema | 1 | 2018 | 456 | 0.130 |
Why?
|
| Glucocorticoids | 1 | 2021 | 2125 | 0.110 |
Why?
|
| Immunologic Factors | 1 | 2021 | 1578 | 0.110 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2018 | 1055 | 0.100 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 2930 | 0.100 |
Why?
|
| Aquaporin 4 | 2 | 2022 | 120 | 0.100 |
Why?
|
| DNA, Viral | 2 | 2015 | 2287 | 0.100 |
Why?
|
| Pituitary Neoplasms | 1 | 2018 | 1287 | 0.100 |
Why?
|
| Viral Load | 2 | 2015 | 3231 | 0.090 |
Why?
|
| Stem Cells | 1 | 2022 | 3593 | 0.090 |
Why?
|
| Humans | 15 | 2022 | 708843 | 0.090 |
Why?
|
| Intensive Care Units | 1 | 2021 | 3418 | 0.080 |
Why?
|
| Antipsychotic Agents | 1 | 2021 | 3033 | 0.080 |
Why?
|
| Middle Aged | 6 | 2022 | 213752 | 0.070 |
Why?
|
| Monocytes | 1 | 2015 | 2660 | 0.070 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 4969 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 16008 | 0.060 |
Why?
|
| Schizophrenia | 1 | 2021 | 6663 | 0.060 |
Why?
|
| Serum | 1 | 2014 | 219 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 13274 | 0.060 |
Why?
|
| Antipyretics | 1 | 2021 | 21 | 0.060 |
Why?
|
| Blood Donors | 1 | 2014 | 355 | 0.050 |
Why?
|
| Female | 6 | 2022 | 375205 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2022 | 61932 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2022 | 71483 | 0.050 |
Why?
|
| Saliva | 1 | 2014 | 793 | 0.050 |
Why?
|
| Adult | 4 | 2022 | 211041 | 0.050 |
Why?
|
| Recurrence | 2 | 2021 | 8255 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2021 | 41081 | 0.040 |
Why?
|
| Acetaminophen | 1 | 2021 | 540 | 0.040 |
Why?
|
| Male | 6 | 2021 | 349524 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 1719 | 0.040 |
Why?
|
| Optic Nerve | 1 | 2020 | 558 | 0.040 |
Why?
|
| Steroids | 1 | 2022 | 880 | 0.040 |
Why?
|
| Infant | 1 | 2018 | 34261 | 0.040 |
Why?
|
| Receptors, CCR | 1 | 2015 | 36 | 0.040 |
Why?
|
| Central Nervous System Diseases | 1 | 2020 | 532 | 0.040 |
Why?
|
| Receptors, CXCR | 1 | 2015 | 52 | 0.040 |
Why?
|
| Paraparesis, Tropical Spastic | 1 | 2014 | 28 | 0.030 |
Why?
|
| Brain | 1 | 2021 | 24969 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 34151 | 0.030 |
Why?
|
| Aged | 3 | 2022 | 161488 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2020 | 1505 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2022 | 1976 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2015 | 1594 | 0.020 |
Why?
|
| Vaccination | 1 | 2021 | 2864 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 29262 | 0.020 |
Why?
|
| Age Factors | 1 | 2021 | 18712 | 0.020 |
Why?
|
| Cell Movement | 1 | 2015 | 5489 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 4383 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2015 | 4254 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 15252 | 0.010 |
Why?
|
| Quality of Life | 1 | 2020 | 11594 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 8877 | 0.010 |
Why?
|
| Time Factors | 1 | 2021 | 41038 | 0.010 |
Why?
|
| Prognosis | 1 | 2018 | 28919 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2018 | 23284 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 19423 | 0.010 |
Why?
|
| Risk Factors | 1 | 2021 | 69553 | 0.010 |
Why?
|
| Young Adult | 1 | 2020 | 55940 | 0.010 |
Why?
|
| Adolescent | 1 | 2020 | 84718 | 0.010 |
Why?
|
| Animals | 1 | 2020 | 170486 | 0.010 |
Why?
|